A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (Pet) With Ligand [11C]PF-04171252 Following Single Oral Dose Administration Of PF-05212365 (SAM-531) In Healthy Subjects.

Trial Profile

A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (Pet) With Ligand [11C]PF-04171252 Following Single Oral Dose Administration Of PF-05212365 (SAM-531) In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2011

At a glance

  • Drugs Cerlapirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Oct 2011 PF 05212365 is called cerlapirdine.
    • 21 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top